Cytek Biosciences Inc (CTKB)vsEdwards Lifesciences Corp (EW)
CTKB
Cytek Biosciences Inc
$4.61
+1.77%
HEALTHCARE · Cap: $599.22M
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 3050% more annual revenue ($6.51B vs $206.71M). EW leads profitability with a 15.4% profit margin vs -39.0%. EW earns a higher WallStSmart Score of 55/100 (C).
CTKB
Hold41
out of 100
Grade: D
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+40.6%
Fair Value
$7.34
Current Price
$4.61
$2.73 discount
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
Smaller company, higher risk/reward
ROE of -25.0% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.19 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 41/100), backed by strong 15.4% margins and 13.6% revenue growth. CTKB offers better value entry with a 40.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer diagnostics, and drug development. The company leverages its proprietary technologies to meet the growing demand for precision in cellular analytics, positioning itself as a key player in the biotechnology sector. With a robust product portfolio and a commitment to exceptional customer support, Cytek is well-equipped to drive transformative discoveries, ultimately enhancing healthcare outcomes and addressing critical challenges in the life sciences.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?